Menu Search
Equities

Takara Bio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TF2:STU

Takara Bio Inc

Actions
  • Price (EUR)4.16
  • Today's Change-0.12 / -2.80%
  • Shares traded0.00
  • 1 Year change-25.71%
  • Beta0.7840
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Takara Bio Inc is a Japan-based company primarily engaged in businesses related to reagents, instruments, contract services and gene therapy. The Company has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The Company also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.

  • Revenue in JPY (TTM)44.15bn
  • Net income in JPY-7.20bn
  • Incorporated2002
  • Employees1.78k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.